The efficacy and safety of anlotinib in refractory colorectal cancer: A double-blinded, placebo controlled, randomized phase III ALTER0703 trial.

Yihebali Chi,Shu Yongqian,Ba Yi,Bai Yuxian,Qin Baoli,Wang Xiuwen,Xiong Jianping,Xu Nong,Zhang Helong,Xu Jianming, Cheng Ying,Feng Jifeng,Hu Chunhong,Chen Yigui,Chen Zhendong,Wang Jufeng, Dang Chenxue,Cai Jianqiang

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 2|浏览50

暂无评分

摘要

65Background: The efficacy of late line treatments for metastatic colorectal cancer (mCRC) is still limited. Antiangiogenic therapy is one of standard treatments in mCRC. Anlotinib is a multitarget...

查看译文

关键词

Placebo,Colorectal cancer,Refractory,Oncology,Medicine,Antiangiogenic therapy,Double blinded,Internal medicine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要